A phase III randomized, open-label multicenter trial to evaluate the benefit of leuprorelin acetate for 24 months after radical prostatectomy in patients with high risk of recurrence (AFU-GETUG 20/0310).
Francois Rozet
No relevant relationships to disclose
Muriel Habibian
No relevant relationships to disclose
Jocelyne Berille
No relevant relationships to disclose
Lise Roca
No relevant relationships to disclose
Laurent Salomon
No relevant relationships to disclose
Michel Soulie
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose